Literature DB >> 30155766

Catecholamine-Synthesizing Enzymes in Pheochromocytoma and Extraadrenal Paraganglioma.

Sachiko Konosu-Fukaya1,2, Kei Omata3, Yuta Tezuka3,4, Yoshikiyo Ono3, Yayoi Aoyama5, Fumitoshi Satoh3,4, Fumiyoshi Fujishima2,5, Hironobu Sasano2,5, Yasuhiro Nakamura6,7.   

Abstract

In chromaffin cells, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), dopamine β-hydroxylase (DBH), and phenylethanolamine N-methyltransferase (PNMT) are mainly involved in catecholamine synthesis. In this study, we evaluated the association between the status of catecholamine-synthesizing enzymes and histopathological features of pheochromocytoma and extraadrenal paraganglioma with special emphasis upon their postoperative clinical behavior. Immunohistochemical evaluation of TH, DBH, AADC, PNMT, Ki 67, and S-100 was performed in 29 pheochromocytoma and 10 extraadrenal paraganglioma and one lymph node harboring metastatic pheochromocytoma. Among these cases, metastasis was subsequently developed in three cases. Urinary normetanephrine (U-NM) levels were significantly higher in clinical metastatic cases than non-metastatic ones. Ki 67 labeling index was significantly higher in both clinical metastatic cases and the Adrenal Gland Scaled Score (PASS) score of ≧ 4 cases than PASS < 4 cases, although this score was originally used in pheochromocytoma. H-score of AADC and DBH were significantly lower in PASS ≧ 4 cases than those with < 4 cases, and in the cases associated with intratumoral necrosis (n = 4), the presence of spindle shaped tumor cells (n = 4), and large nests of cells or diffuse growth (n = 5). Lower status of intratumoral AADC could be related to poor differentiation of tumor cells in both catecholamine production and morphology and could be related to aggressive biological behavior of both pheochromocytoma and extraadrenal paraganglioma.

Entities:  

Keywords:  Adrenal gland scaled score (PASS); Catecholamine-synthesizing enzyme; Extraadrenal paraganglioma; Immunohistochemistry; Pheochromocytoma

Mesh:

Substances:

Year:  2018        PMID: 30155766     DOI: 10.1007/s12022-018-9544-5

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  35 in total

1.  Pheochromocytoma: time to stamp out "malignancy"?

Authors:  Arthur S Tischler
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

2.  Properties of the nerve growth factor receptor of a clonal line of rat pheochromocytoma (PC12) cells.

Authors:  K Herrup; H Thoenen
Journal:  Exp Cell Res       Date:  1979-06       Impact factor: 3.905

3.  Reciprocal regulation of the content of aromatic L-amino acid decarboxylase and tyrosine hydroxylase mRNA by NGF in PC12 cells.

Authors:  X M Li; J Qi; A V Juorio; A A Boulton
Journal:  J Neurosci Res       Date:  1997-02-15       Impact factor: 4.164

4.  Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine.

Authors:  Graeme Eisenhofer; David S Goldstein; Patricia Sullivan; Gyorgy Csako; Frederieke M Brouwers; Edwin W Lai; Karen T Adams; Karel Pacak
Journal:  J Clin Endocrinol Metab       Date:  2005-01-11       Impact factor: 5.958

5.  Dopamine-secreting pheochromocytoma: an unrecognized entity? Classification of pheochromocytomas according to their type of secretion.

Authors:  C Proye; P Fossati; P Fontaine; J Lefebvre; M Decoulx; J L Wemeau; D Dewailly; E Rwamasirabo; P Cecat
Journal:  Surgery       Date:  1986-12       Impact factor: 3.982

6.  In vitro and in vivo angiogenesis in PC12 pheochromocytoma cells is mediated by vascular endothelial growth factor.

Authors:  M Middeke; S Hoffmann; I Hassan; A Wunderlich; L C Hofbauer; A Zielke
Journal:  Exp Clin Endocrinol Diabetes       Date:  2002-11       Impact factor: 2.949

7.  Dopa-decarboxylation in the striata of rats with unilateral substantia nigra lesions.

Authors:  U J Kang; D H Park; T Wessel; H Baker; T H Joh
Journal:  Neurosci Lett       Date:  1992-11-23       Impact factor: 3.046

Review 8.  Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas.

Authors:  Aoife J Lowery; Siun Walsh; Enda W McDermott; Ruth S Prichard
Journal:  Oncologist       Date:  2013-04-10

9.  The management of benign and malignant pheochromocytoma and abdominal paraganglioma.

Authors:  E Edström Elder; A-L Hjelm Skog; A Höög; B Hamberger
Journal:  Eur J Surg Oncol       Date:  2003-04       Impact factor: 4.424

10.  Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma.

Authors:  Jung-Min Koh; Seong Hee Ahn; Hyeonmok Kim; Beom-Jun Kim; Tae-Yon Sung; Young Hoon Kim; Suck Joon Hong; Dong Eun Song; Seung Hun Lee
Journal:  PLoS One       Date:  2017-11-08       Impact factor: 3.240

View more
  7 in total

1.  PHOX2B is a Sensitive and Specific Marker for the Histopathological Diagnosis of Pheochromocytoma and Paraganglioma.

Authors:  Minami Miyauchi; Takumi Akashi; Asuka Furukawa; Keisuke Uchida; Tomoki Tamura; Noboru Ando; Susumu Kirimura; Hiroshi Shintaku; Kurara Yamamoto; Takashi Ito; Keiko Miura; Kou Kayamori; Yosuke Ariizumi; Takahiro Asakage; Atsushi Kudo; Minoru Tanabe; Yasuhisa Fujii; Hironori Ishibashi; Kenichi Okubo; Masanori Murakami; Tetsuya Yamada; Akira Takemoto; Yuan Bae; Yoshinobu Eishi; Kenichi Ohashi
Journal:  Endocr Pathol       Date:  2022-08-27       Impact factor: 4.056

Review 2.  The systems of metastatic potential prediction in pheochromocytoma and paraganglioma.

Authors:  Yong Wang; Minghao Li; Hao Deng; Yingxian Pang; Longfei Liu; Xiao Guan
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

Review 3.  Data set for the reporting of pheochromocytoma and paraganglioma: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting.

Authors:  Lester D R Thompson; Anthony J Gill; Sylvia L Asa; Roderick J Clifton-Bligh; Ronald R de Krijger; Noriko Kimura; Paul Komminoth; Ernest E Lack; Jacques W M Lenders; Ricardo V Lloyd; Thomas G Papathomas; Peter M Sadow; Arthur S Tischler
Journal:  Hum Pathol       Date:  2020-05-11       Impact factor: 3.466

Review 4.  Intricacies of the Molecular Machinery of Catecholamine Biosynthesis and Secretion by Chromaffin Cells of the Normal Adrenal Medulla and in Pheochromocytoma and Paraganglioma.

Authors:  Annika M A Berends; Graeme Eisenhofer; Lauren Fishbein; Anouk N A V D Horst-Schrivers; Ido P Kema; Thera P Links; Jacques W M Lenders; Michiel N Kerstens
Journal:  Cancers (Basel)       Date:  2019-08-06       Impact factor: 6.639

5.  Glutaminases as a Novel Target for SDHB-Associated Pheochromocytomas/Paragangliomas.

Authors:  Balazs Sarkadi; Katalin Meszaros; Ildiko Krencz; Letizia Canu; Lilla Krokker; Sara Zakarias; Gabor Barna; Anna Sebestyen; Judit Papay; Zoltan Hujber; Henriett Butz; Otto Darvasi; Peter Igaz; Judit Doczi; Michaela Luconi; Christos Chinopoulos; Attila Patocs
Journal:  Cancers (Basel)       Date:  2020-03-05       Impact factor: 6.639

Review 6.  Recent Advances in Histopathological and Molecular Diagnosis in Pheochromocytoma and Paraganglioma: Challenges for Predicting Metastasis in Individual Patients.

Authors:  Yuto Yamazaki; Xin Gao; Alessio Pecori; Yasuhiro Nakamura; Yuta Tezuka; Kei Omata; Yoshikiyo Ono; Ryo Morimoto; Fumitoshi Satoh; Hironobu Sasano
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-27       Impact factor: 5.555

7.  Histopathological Analysis of Tumor Microenvironment and Angiogenesis in Pheochromocytoma.

Authors:  Xin Gao; Yuto Yamazaki; Alessio Pecori; Yuta Tezuka; Yoshikiyo Ono; Kei Omata; Ryo Morimoto; Yasuhiro Nakamura; Fumitoshi Satoh; Hironobu Sasano
Journal:  Front Endocrinol (Lausanne)       Date:  2020-11-10       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.